Luke, J. J., Davarifar, A., Najjar, Y. G., Hamid, O., Schadendorf, D., Wong, M. K., Khushalani, N. I., Ascierto, P. A., Bowles, T. L., Navarro, M., Gullo, G., Robert, C. (2025). A randomized, controlled, multicenter, phase 3 study of vusolimogene oderparepvec combined with nivolumab vs treatment of physician’s choice in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps9599